(Q36619058)

15 August 2017

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer (English)

1 reference

15 August 2017

metastatic breast cancer

1 reference

9

Schally AV

1 reference

15 August 2017

O'Byrne KJ

1

1 reference

15 August 2017

Dobbs N

2

1 reference

15 August 2017

Propper DJ

3

1 reference

15 August 2017

Braybrooke JP

4

1 reference

15 August 2017

Koukourakis MI

5

1 reference

15 August 2017

Mitchell K

6

1 reference

15 August 2017

Woodhull J

7

1 reference

15 August 2017

Talbot DC

8

1 reference

15 August 2017

Harris AL

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

79

1 reference

15 August 2017

9-10

1 reference

15 August 2017

1413-1418

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690226

15 August 2017

0 references

cites work

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Analysis of somatostatin receptor subtype mRNA expression in human breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Endocrine therapies of breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Somatostatin and somatostatin analogues in human breast carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Prognostic factors and response to therapy in breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Molecular pharmacology of somatostatin-receptor subtypes.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Somatostatin-receptor scintigraphy in primary breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Treatment of metastatic breast cancer: present and future prospects.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Somatostatin (second of two parts).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Oncological applications of somatostatin analogues

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Protein antigen-monoclonal antibody contact sites investigated by limited proteolysis of monoclonal antibody-bound antigen: protein "footprinting".

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Mechanisms of antineoplastic action of somatostatin analogs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Insulin-like growth factors in breast cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Tamoxifen and somatostatin affect tumours by inducing apoptosis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362707

Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma

20 September 2018

1 reference

12 December 2020

Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells

1 reference

12 December 2020

Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer

1 reference

12 December 2020

Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin

1 reference

12 December 2020

Advanced breast cancer: response to somatostatin

1 reference

12 December 2020

Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours

1 reference

12 December 2020

Differential effects of LHRH and somatostatin analogs on human breast cancer

1 reference

12 December 2020

Insulin-like growth factors and cancer

1 reference

12 December 2020

A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice

1 reference

12 December 2020

Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis

1 reference

12 December 2020

Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas

1 reference

12 December 2020

Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate

1 reference

12 December 2020

Insulin-like growth factor-I and new opportunities for cancer prevention

1 reference

12 December 2020

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

1 reference

12 December 2020

Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer

1 reference

12 December 2020

Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice

1 reference

12 December 2020

Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels

1 reference

12 December 2020

Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo

1 reference

12 December 2020

Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells

1 reference

12 December 2020

Octreotide as first-line treatment for women with metastatic breast cancer

1 reference

12 December 2020

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6690226

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

10188884

1 reference